CA2491131C - Nouveaux composes utilises comme inhibiteurs de l'histone-deacetylase - Google Patents

Nouveaux composes utilises comme inhibiteurs de l'histone-deacetylase Download PDF

Info

Publication number
CA2491131C
CA2491131C CA2491131A CA2491131A CA2491131C CA 2491131 C CA2491131 C CA 2491131C CA 2491131 A CA2491131 A CA 2491131A CA 2491131 A CA2491131 A CA 2491131A CA 2491131 C CA2491131 C CA 2491131C
Authority
CA
Canada
Prior art keywords
enyl
cancer
group
disease
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2491131A
Other languages
English (en)
Other versions
CA2491131A1 (fr
Inventor
Alexander B. Maurer
Sascha Hoevelmann
Elke Martin
Bernd Hentsch
Michael Gassen
Juergen Kraus
Rolf Krauss
Adam-Spencer Vincek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
4SC AG
Original Assignee
4SC Discovery GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4SC Discovery GmbH filed Critical 4SC Discovery GmbH
Publication of CA2491131A1 publication Critical patent/CA2491131A1/fr
Application granted granted Critical
Publication of CA2491131C publication Critical patent/CA2491131C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne des composés correspondant à la formule générale (I), ou bien des sel pharmaceutiquement acceptables ou des dérivés physiologiquement fonctionnels de ces composés. Dans ladite formule (I): n représente un cycle non aromatique contenant deux à sept atomes de carbone, le système cyclique pouvant contenir au moins deux doubles liaisons; X représente C, CH ou CH¿2?; Y est sélectionné parmi C, CH, CH¿2?, S, NR, CH¿2?-CH¿2?, H¿2?C- -CH, HC- -CH¿2?, C- -CH¿2?, H¿2?C- -C, ou bien C- -C, au moins un des atomes hydrogènes pouvant être éventuellement substitué par au moins un substituant R'; chacune des lignes pointillées représente une liaison simple, double ou triple, une combinaison d'une triple liaison et d'une triple liaison, ainsi que d'une double liaison et d'une triple liaison étant exclue; les symboles R' représentent, indépendamment l'un de l'autre, H, -CN, alkyle, cycloalkyle, aminoalkyle, alkylamino, alcoxy, -OH, -SH, alkylthio, hydroxyalkyle, hydroxyalkylamino, halogène, haloalkyle, haloalkyloxy; R représente H, un groupe alkyle ou cycloalkyle; Z représente CH, C, ou P; p vaut 0 ou 1.
CA2491131A 2002-07-23 2003-07-17 Nouveaux composes utilises comme inhibiteurs de l'histone-deacetylase Expired - Fee Related CA2491131C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10233412A DE10233412A1 (de) 2002-07-23 2002-07-23 Neue Verbindungen als Histondeacetylase-Inhibitoren
DE10233412.9 2002-07-23
PCT/EP2003/007794 WO2004009536A1 (fr) 2002-07-23 2003-07-17 Nouveaux composes utilises comme inhibiteurs de l'histone-deacetylase

Publications (2)

Publication Number Publication Date
CA2491131A1 CA2491131A1 (fr) 2004-01-29
CA2491131C true CA2491131C (fr) 2013-05-07

Family

ID=30128280

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2491131A Expired - Fee Related CA2491131C (fr) 2002-07-23 2003-07-17 Nouveaux composes utilises comme inhibiteurs de l'histone-deacetylase

Country Status (6)

Country Link
EP (1) EP1523470A1 (fr)
JP (1) JP4644829B2 (fr)
AU (1) AU2003254371A1 (fr)
CA (1) CA2491131C (fr)
DE (1) DE10233412A1 (fr)
WO (1) WO2004009536A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003076395A1 (fr) 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Derives carbonylamino utilises en tant que nouveaux inhibiteurs d'histone deacetylase
BR0308081A (pt) 2002-03-13 2004-12-21 Janssen Pharmaceutica Nv Inibidores de histona desacetilase
CN1305850C (zh) 2002-03-13 2007-03-21 詹森药业有限公司 作为组蛋白脱乙酰酶新颖抑制剂的磺酰基氨基衍生物
EA007270B1 (ru) 2002-03-13 2006-08-25 Янссен Фармацевтика Н.В. Пиперазинил-, пиперидинил- и морфолинилпроизводные как новые ингибиторы гистондеацетилазы
ME01058B (fr) 2004-07-28 2012-10-20 Janssen Pharmaceutica Nv Derives de piperazine de propenyle substituee comme nouveaux inhibiteurs de l'histone deacetylase
WO2006010750A1 (fr) 2004-07-28 2006-02-02 Janssen Pharmaceutica N.V. Derives d'indolyl alkyl amine substitues utilises en tant que nouveaux inhibiteurs d'histone deacetylase
NZ589276A (en) 2005-02-03 2012-06-29 Topotarget Uk Ltd Combination therapies using hdac inhibitors and erlotinib (tarceva)
KR101340824B1 (ko) 2005-05-13 2013-12-11 토포타겟 유케이 리미티드 Ｈｄａｃ 억제제의 약학 제형
CA2605272C (fr) 2005-05-18 2013-12-10 Janssen Pharmaceutica N.V. Derives substitues d'aminopropenyl-piperidine ou de morpholine utilises en tant qu'inhibiteurs de l'histone-desacetylase
JP2009501236A (ja) 2005-07-14 2009-01-15 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
DK1943232T3 (da) * 2005-10-27 2011-08-29 Janssen Pharmaceutica Nv Kvadratsyrederivater som inhibitorer af histondeacetylase
CA2627923C (fr) 2005-11-10 2016-01-12 Topotarget Uk Limited Inhibiteurs d'histone desacetylase (hdac) pour le traitement du cancer
ATE539073T1 (de) 2006-01-19 2012-01-15 Janssen Pharmaceutica Nv Heterocyclylalkylderivate als neue inhibitoren von histondeacetylase
CN101370790B (zh) 2006-01-19 2015-10-21 詹森药业有限公司 作为组蛋白去乙酰化酶抑制剂的吡啶和嘧啶衍生物
CA2631876C (fr) 2006-01-19 2014-05-27 Janssen Pharmaceutica N.V. Derives d'aminophenyle en tant qu'inhibiteurs d'histone desacetylase
EP1979327A1 (fr) 2006-01-19 2008-10-15 Janssen Pharmaceutica, N.V. Dérivés de pyridine et de pyrimidine en tant qu'inhibiteurs d'histone désacétylase
CA2633100C (fr) 2006-01-19 2014-12-09 Janssen Pharmaceutica N.V. Derives de pyridine et de pyrimidine en tant qu'inibiteurs d'histone desacetylase
JP5137849B2 (ja) 2006-01-19 2013-02-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼのインヒビターとしての置換インドリル−アルキル−アミノ−誘導体
MX2010003230A (es) 2007-09-25 2010-04-07 Topotarget Uk Ltd Metodos para la sintesis de ciertos compuestos de acido hidroxamico.
JP5564033B2 (ja) 2008-03-27 2014-07-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼの新規インヒビターとしてのアザ−ビシクロヘキシル置換インドリルアルキルアミノ誘導体
CN102659630B (zh) * 2011-05-04 2016-01-06 成都地奥九泓制药厂 一种异羟肟酸类化合物及其制备方法和用途
TWI650139B (zh) * 2017-10-11 2019-02-11 行政院原子能委員會核能硏究所 含有放射性同位素氟的異羥肟酸類造影劑、其製備方法及其用途
KR102236356B1 (ko) * 2017-11-24 2021-04-05 주식회사 종근당 루푸스의 예방 또는 치료를 위한 조성물
KR20190118251A (ko) * 2018-04-10 2019-10-18 주식회사 종근당 건성안의 예방 또는 치료를 위한 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50121218A (fr) * 1974-03-01 1975-09-23
US3994997A (en) * 1975-05-09 1976-11-30 Gulf Oil Corporation O,O-diethyl-O-carboxamidophosphate esters
US4604407A (en) * 1985-04-04 1986-08-05 E. R. Squibb & Sons, Inc. Hydroxamates
JPH01221371A (ja) * 1988-02-29 1989-09-04 Hokko Chem Ind Co Ltd 環状オキシアミン誘導体の製造方法
US6043389A (en) * 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
JP4269041B2 (ja) * 1999-03-02 2009-05-27 国立大学法人九州工業大学 新規な環状テトラペプチド誘導体とその医薬用途
JP2001081031A (ja) * 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
WO2001070675A2 (fr) * 2000-03-24 2001-09-27 Methylgene, Inc. Inhibiteurs d'histone desacetylase

Also Published As

Publication number Publication date
JP2005533840A (ja) 2005-11-10
CA2491131A1 (fr) 2004-01-29
JP4644829B2 (ja) 2011-03-09
EP1523470A1 (fr) 2005-04-20
AU2003254371A1 (en) 2004-02-09
WO2004009536A1 (fr) 2004-01-29
DE10233412A1 (de) 2004-02-12

Similar Documents

Publication Publication Date Title
CA2491131C (fr) Nouveaux composes utilises comme inhibiteurs de l'histone-deacetylase
CN110088105B (zh) Jak家族激酶的小分子抑制剂
JP4405602B2 (ja) ヒストン脱アセチル化酵素阻害剤
US8318808B2 (en) Zn2+chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors
US8227516B2 (en) Compounds as histone deacetylase inhibitors
BG107889A (bg) Тетралонови производни като антитуморни средства
JPH11335375A (ja) ヒストン脱アセチル化酵素阻害作用を有するベンズアミド誘導体
US11578058B2 (en) Heterocyclic compounds for inhibiting TYK2 activities
WO2000015603A1 (fr) Derives de benzene et leur utilisation medicale
CN104010501A (zh) 含src同源区2蛋白酪胺酸磷酸酶-1增效剂及其治疗方法
JPH10182583A (ja) 新規ヒドロキサム酸誘導体
EP3519383B1 (fr) Dérivés de rétinoïde à activité antitumorale
CN103848795B (zh) 一种1,2,5-噁二唑-2-氧化物组蛋白去乙酰化酶抑制剂及其制备方法和应用
CN101883487A (zh) 抑制异戊二烯基-s-半胱氨酰基甲基转移酶的酸模拟化合物
CN109602734A (zh) 用于治疗白血病的化合物和方法
JP7254703B2 (ja) Ｒｏｒガンマモジュレーター及びその使用
JP2020505412A (ja) Ｒｏｒガンマモジュレーター及びその使用
EA023171B1 (ru) Тиопроизводные лактамов в качестве высокоактивных ингибиторов hdac и их применение в качестве лекарственных средств
CN107556315B (zh) 含四元环的咪唑衍生物
CN113149867B (zh) 一种姜黄素组蛋白去乙酰化酶抑制剂及其制备方法和医药用途
CN113402414A (zh) 一种苯甲酸衍生物及其制法和药物用途
WO2024173522A1 (fr) Inhibiteurs du domaine n-terminal du récepteur des androgènes
CN115873018A (zh) 苯并嘧啶和苯并三嗪类造血祖细胞激酶1降解剂及其应用

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150717